Mosaic ImmunoEngineering Inc.

For the period ended Dec 31, 2025. Filed Apr 15, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Apr 15, 2026

CPMVStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

	December 31, 2025	December 31, 2024
ASSETS
Current assets:
Cash and cash equivalents	$3,622	$115,019
Prepaid expenses and other current assets	16,260	26,592
Total current assets	19,882	141,611
Total assets	$19,882	$141,611
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable	$132,784	$134,865
Accrued compensation	4,254,208	3,767,652
Accrued consulting	787,903	787,903
Accrued expenses and other	655,160	646,850
Loan payable	200,000	200,000
Total current liabilities	6,030,055	5,537,270
Convertible notes, net	1,465,847	1,392,515
Total liabilities	7,495,902	6,929,785
Commitments and contingencies	–	–
Stockholders’ deficit:
Preferred stock, $0.00001 par value; 5,000,000 shares authorized:	–	–
Series A Convertible Voting Preferred Stock; 630,000 shares designated; no shares issued and outstanding	–	–
Series B Convertible Voting Preferred Stock; 70,000 shares designated; 70,000 shares issued and outstanding	1	1
Common stock, $0.00001 par value: 100,000,000 shares authorized: 7,242,137 shares issued and outstanding	72	72
Additional paid-in capital	2,050,073	2,050,073
Accumulated deficit	(9,526,166)	(8,838,320)
Total stockholders’ deficit	(7,476,020)	(6,788,174)
Total liabilities and stockholders’ deficit	$19,882	$141,611

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.